NEUPOGEN J Code: J1442

Drug & Product Overview

HCPCS Descriptor Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram

HCPCS Added Date January 1, 2014

Manufacturer Amgen

Route of Administration Intravenous, Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About NEUPOGEN

Neupogen is a medication aligned to the HCPCS J Code: J1442 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology Colony Stimulating Factor, it is administered via the intravenous or subcutaneous routes and manufactured by Amgen.

According to CMS Drug Use Information: Filgrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Filgrastim is given to people whose ability to make white blood cells is reduced (for instance, due to chemotherapy, chronic neutropenia, or exposure to large amounts of radiation). It is also used in certain treatment procedures (such as bone marrow/stem cell transplant). This monograph is about the following filgrastim products: filgrastim, filgrastim-aafi, filgrastim-ayow, filgrastim-laha, filgrastim-sndz, filgrastim-txid, and tbo-filgrastim.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 5 of 14 NDCs — log in for the full crosswalk.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
55513-0209-10	Neupogen	Amgen, Inc	4800	480 MCG / 0.8 ML
55513-0209-20	Neupogen	Amgen, Inc	4800	480 MCG / 0.8 ML
55513-0530-10	Neupogen	Amgen, Inc	3000	300 MCG / 1 ML
55513-0546-10	Neupogen	Amgen, Inc	4800	480 MCG / 1.6 ML
55513-0924-10	Neupogen	Amgen, Inc	3000	300 MCG / 0.5 ML
•••••-••••-•• Log in to view	NEUPOGEN
	NEUPOGEN
	NEUPOGEN

Login to view 9 more NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

NEUPOGEN Pricing & Reimbursement

J1442 Private Payer Reimbursement

$1.03 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q4 2026

Filgrastim Biosimilar Information:

NEUPOGEN Approval Date: February 20, 1991

Product Name	HCPCS Code	Active Ingredient	BLA Type
Neupogen	J1442	Filgrastim	351(a) Originator Product
Zarxio	Q5101	Filgrastim	351(k) Biosimilar
Nivestym	Q5110	Filgrastim	351(k) Biosimilar
Releuko	Q5125	Filgrastim	351(k) Biosimilar
Nypozi	Q5148	Filgrastim	351(k) Biosimilar
Filkri	Q5172	Filgrastim	351(k) Biosimilar

NEUPOGEN Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 14.47%

Avg. Days to File 8.6days

Avg. Days to Pay 22.8days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J1442 claims analytics on FocalPoint →

NEUPOGEN CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

JW / JZ modifiers apply

CMS has identified Neupogen (J1442) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

NEUPOGEN Medically Unlikely Edits (MUE)

The most billing units of J1442 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mcg.

Practitioner Office & Hospital Outpatient

1,500 units / day

= 1,500 mcg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

NEUPOGEN Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute myeloid leukemia Autologous peripheral blood progenitor cell collection and therapy Cancer receiving myelosuppressive chemotherapy Cancer undergoing bone marrow transplantation Hematopoietic syndrome of acute radiation syndrome Severe chronic neutropenia

Drug Class

Granulocyte Colony-Stimulating Factor [CS]Increased Myeloid Cell Production [PE]Leukocyte Growth Factor [EPC]

Frequently Asked Questions

Is there an available Neupogen billing and coding guide?

Billing and coding information for NEUPOGEN can be found through Amgen. Visit Here →

Are there any available Neupogen patient assistance programs?

NEUPOGEN patient assistance information can be found through Amgen. Visit Here →

Where can I find Neupogen prescribing information?

NEUPOGEN prescribing information can be found at the link below: Visit Here →

Where can I find Neupogen side effect information?

Information regarding NEUPOGEN's side effects can be found at MedlinePlus Visit Here →

Does billing NEUPOGEN require JZ/JW wastage modifiers?

CMS has identified NEUPOGEN(J1442) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.